Zhang Xinyan, Hunt Peter W, Hammer Scott M, Cespedes Michelle S, Patterson Kristine B, Bosch Ronald J
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
HIV Clin Trials. 2013 Mar-Apr;14(2):61-7. doi: 10.1310/hct1402-61.
While persistent T-cell activation has been cross-sectionally associated with poor CD4+ T-cell restoration in HIV-infected individuals maintaining antiretroviral treatment (ART)-mediated viral suppression, it remains unclear whether CD8+ T-cell activation is of predictive effect on CD4+ T-cell recovery.
We assessed whether the extent of persistent CD8+ T-cell activation (% CD38+/HLA-DR+) in the first few years of ART-mediated viral suppression predicted subsequent CD4+ T-cell recovery in 95 subjects with up to 15 years of observation on suppressive ART.
Lower CD8+ T-cell activation and higher naïve CD4+ T-cell frequencies (CD45RA+/CD62L+) measured at year 3 to 5 after starting ART independently predicted greater subsequent CD4+ T-cell increases. The mean CD4 count increase from year 0 to year 5 and the increase to the average of year 10 to 15 in the low CD8 activation group (≤18.5%; mean = 13%) were 342 and 458 cells/mm,3 and the increases were 248 and 349 cells/mm3 for the high CD8 activation group (≯18.5%; mean = 29%) (P = .002 and P = .016, respectively, comparing groups). At years 10 to 15, the mean CD4 counts in the groups were 579 and 484 cells/mm3, respectively (P = .026).
These findings support the need to identify approaches to reduce immune activation in treated HIV disease.
在接受抗逆转录病毒治疗(ART)且病毒得到抑制的HIV感染者中,持续性T细胞激活与CD4+T细胞恢复不良呈横断面关联,但CD8+T细胞激活对CD4+T细胞恢复是否具有预测作用尚不清楚。
我们评估了在接受ART治疗且病毒得到抑制的最初几年中,持续性CD8+T细胞激活程度(%CD38+/HLA-DR+)是否能预测95例接受长达15年抑制性ART治疗患者随后的CD4+T细胞恢复情况。
开始ART治疗后第3至5年测得的较低CD8+T细胞激活水平和较高的初始CD4+T细胞频率(CD45RA+/CD62L+)独立预测了随后更大的CD4+T细胞增加。低CD8激活组(≤18.5%;平均值=13%)从第0年到第5年的平均CD4细胞计数增加以及到第10至15年平均值的增加分别为342和458个细胞/mm³,高CD8激活组(>18.5%;平均值=29%)的增加分别为248和349个细胞/mm³(比较两组,P分别为0.002和0.016)。在第10至15年,两组的平均CD4细胞计数分别为579和484个细胞/mm³(P=0.026)。
这些发现支持需要确定降低治疗的HIV疾病中免疫激活的方法。